18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.

Détails

Ressource 1Télécharger: BIB_5BB3E831A933.P001.pdf (685.77 [Ko])
Etat: Public
Version: Author's accepted manuscript
ID Serval
serval:BIB_5BB3E831A933
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
Périodique
Melanoma Research
Auteur⸱e⸱s
Orcurto V., Denys A., Voelter V., Schalenbourg A., Schnyder P., Zografos L., Leyvraz S., Delaloye A.B., Prior J.O.
ISSN
1473-5636 (Electronic)
ISSN-L
0960-8931
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
22
Numéro
1
Pages
63-69
Langue
anglais
Notes
Publication types: JOURNAL ARTICLEPublication
Résumé
PURPOSE: F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and MRI are used for detecting liver metastases from uveal melanoma. The introduction of new treatment options in clinical trials might benefit from early response assessment. Here, we determine the value of FDG-PET/CT with respect to MRI at diagnosis and its potential for monitoring therapy. MATERIAL AND METHODS: Ten patients with biopsy-proven liver metastases of uveal melanoma enrolled in a randomized phase III trial (NCT00110123) underwent both FDG-PET coupled with unenhanced CT and gadolinium-diethylene triamine pentaacetic acid-enhanced liver MRI within 4 weeks. FDG-PET and MRI were evaluated blindly and then compared using the ratio of lesion to normal liver parenchyma PET-derived standardized uptake value (SUV). The influence of lesion size and response to chemotherapy were studied. RESULTS: Overall, 108 liver lesions were seen: 34 (31%) on both modalities (1-18 lesions/patient), four (4%) by PET/CT only, and 70 (65%) by MRI only. SUV correlated with MRI lesion size (r=0.81, P<0.0001). PET/CT detected 26 of 33 (79%) MRI lesions of more than or equal to 1.2 cm, whereas it detected only eight of 71 (11%) lesions of less than 1.2 cm (P<0.0001). MRI lesions without PET correspondence were small (0.6±0.2 vs. 2.1±1.1 cm, P<0.0001). During follow-up (six patients, 30 lesions), the ratio lesion-to-normal-liver SUV diminished in size-stable lesions (1.90±0.64-1.46±0.50, P<0.0001), whereas it increased in enlarging lesions (1.56±0.40-1.99±0.56, P=0.032). CONCLUSION: MRI outweighs PET/CT for detecting small liver metastases. However, PET/CT detected at least one liver metastasis per patient and changes in FDG uptake not related to size change, suggesting a role in assessing early therapy response.
Pubmed
Web of science
Création de la notice
27/10/2011 15:45
Dernière modification de la notice
20/08/2019 14:14
Données d'usage